Johnson & Johnson Price to Free Cash Flow Ratio 2012-2026 | JNJ
Historical price to free cash flow ratio values for Johnson & Johnson (JNJ) since 2012.
| Johnson & Johnson Price to Free Cash Flow Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM FCF per Share | Price to FCF Ratio |
| 2026-09-15 | 267.20 | 28.65 | |
| 2026-06-30 | 252.72 | $9.33 | 27.10 |
| 2026-03-31 | 241.82 | $7.51 | 32.22 |
| 2025-12-31 | 203.65 | $8.40 | 24.23 |
| 2025-09-30 | 181.32 | $8.25 | 21.97 |
| 2025-06-30 | 148.28 | $7.82 | 18.97 |
| 2025-03-31 | 159.62 | $8.70 | 18.36 |
| 2024-12-31 | 138.09 | $8.45 | 16.35 |
| 2024-09-30 | 153.51 | $8.69 | 17.66 |
| 2024-06-30 | 137.41 | $8.48 | 16.20 |
| 2024-03-31 | 147.53 | $7.59 | 19.43 |
| 2023-12-31 | 145.07 | $7.27 | 19.96 |
| 2023-09-30 | 143.01 | $6.28 | 22.77 |
| 2023-06-30 | 150.89 | $5.63 | 26.82 |
| 2023-03-31 | 140.24 | $6.23 | 22.50 |
| 2022-12-31 | 158.68 | $6.65 | 23.84 |
| 2022-09-30 | 145.80 | $6.80 | 21.45 |
| 2022-06-30 | 157.38 | $7.60 | 20.70 |
| 2022-03-31 | 156.13 | $7.52 | 20.77 |
| 2021-12-31 | 149.74 | $7.65 | 19.56 |
| 2021-09-30 | 140.44 | $8.72 | 16.10 |
| 2021-06-30 | 142.41 | $8.77 | 16.24 |
| 2021-03-31 | 141.19 | $8.14 | 17.34 |
| 2020-12-31 | 134.37 | $7.67 | 17.51 |
| 2020-09-30 | 126.23 | $6.91 | 18.27 |
| 2020-06-30 | 118.45 | $6.65 | 17.82 |
| 2020-03-31 | 109.69 | $8.50 | 12.90 |
| 2019-12-31 | 121.25 | $8.64 | 14.04 |
| 2019-09-30 | 106.80 | $9.35 | 11.43 |
| 2019-06-30 | 114.12 | $8.74 | 13.05 |
| 2019-03-31 | 113.76 | $8.04 | 14.14 |
| 2018-12-31 | 104.32 | $7.97 | 13.10 |
| 2018-09-30 | 110.99 | $7.48 | 14.84 |
| 2018-06-30 | 96.82 | $7.70 | 12.57 |
| 2018-03-31 | 101.51 | $7.36 | 13.78 |
| 2017-12-31 | 109.97 | $7.14 | 15.40 |
| 2017-09-30 | 101.70 | $7.11 | 14.30 |
| 2017-06-30 | 102.83 | $6.62 | 15.53 |
| 2017-03-31 | 96.18 | $6.33 | 15.19 |
| 2016-12-31 | 88.38 | $6.03 | 14.66 |
| 2016-09-30 | 90.00 | $5.86 | 15.35 |
| 2016-06-30 | 91.80 | $6.19 | 14.82 |
| 2016-03-31 | 81.31 | $6.66 | 12.22 |
| 2015-12-31 | 76.63 | $6.96 | 11.01 |
| 2015-09-30 | 69.13 | $6.13 | 11.28 |
| 2015-06-30 | 71.63 | $6.80 | 10.53 |
| 2015-03-31 | 73.40 | $6.56 | 11.19 |
| 2014-12-31 | 75.77 | $6.85 | 11.06 |
| 2014-09-30 | 76.73 | $6.76 | 11.36 |
| 2014-06-30 | 74.81 | $5.83 | 12.84 |
| 2014-03-31 | 69.75 | $5.49 | 12.70 |
| 2013-12-31 | 64.57 | $4.96 | 13.01 |
| 2013-09-30 | 60.69 | $4.94 | 12.30 |
| 2013-06-30 | 59.66 | $4.71 | 12.66 |
| 2013-03-31 | 56.23 | $4.64 | 12.12 |
| 2012-12-31 | 47.96 | $4.97 | 9.66 |
| 2012-09-30 | 46.74 | $5.02 | 9.31 |
| 2012-06-30 | 45.41 | $5.05 | 8.99 |
| 2012-03-31 | 43.91 | $4.83 | 9.10 |
| 2011-12-31 | 43.27 | $4.59 | 9.42 |
| 2011-09-30 | 41.64 | $4.62 | 9.00 |
| 2011-06-30 | 43.10 | $4.71 | 9.15 |
| 2011-03-31 | 38.06 | $4.72 | 8.07 |
| 2010-12-31 | 39.38 | $5.21 | 7.56 |
| 2010-09-30 | 39.11 | $5.76 | 6.79 |
| 2010-06-30 | 36.93 | $5.69 | 6.49 |
| 2010-03-31 | 40.40 | $5.50 | 7.34 |
| 2009-12-31 | 39.61 | $5.15 | 7.69 |
| 2009-09-30 | 37.15 | $4.77 | 7.80 |
| 2009-06-30 | 34.38 | $4.60 | 7.47 |
| 2009-03-31 | 31.56 | $4.36 | 7.24 |
| 2008-12-31 | 35.60 | $4.48 | 7.95 |
| 2008-09-30 | 40.88 | $4.28 | 9.56 |
| 2008-06-30 | 37.72 | $4.03 | 9.36 |
| 2008-03-31 | 37.77 | $4.05 | 9.33 |
| 2007-12-31 | 38.57 | $4.31 | 8.96 |
| 2007-09-30 | 37.76 | $4.49 | 8.41 |
| 2007-06-30 | 35.18 | $4.49 | 7.83 |
| 2007-03-31 | 34.18 | $4.30 | 7.94 |
| 2006-12-31 | 37.23 | $4.08 | 9.12 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $641.804B | $94.193B |
| Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $1071.528B | 36.15 |
| AbbVie (ABBV) | United States | $462.493B | 24.08 |
| Merck (MRK) | United States | $357.370B | 45.12 |
| Roche Holding AG (RHHBY) | Switzerland | $349.105B | 0.00 |
| Novartis AG (NVS) | Switzerland | $265.214B | 16.01 |
| Novo Nordisk (NVO) | Denmark | $194.004B | 10.81 |
| Pfizer (PFE) | United States | $157.995B | 9.09 |
| Sanofi (SNY) | France | $105.050B | 8.84 |
| Bayer (BAYRY) | Germany | $56.081B | 9.98 |
| Innoviva (INVA) | United States | $1.510B | 5.16 |